Lung Cancer Dispatch
4.5K views | +1 today
Follow
Lung Cancer Dispatch
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Scooped by Cancer Commons
Scoop.it!

Potential Lung Cancer Vaccine Shows Renewed Promise

Potential Lung Cancer Vaccine Shows Renewed Promise | Lung Cancer Dispatch | Scoop.it

"Researchers at UC Davis have found that the investigational cancer vaccine tecemotide, when administered with the chemotherapeutic cisplatin, boosted immune response and reduced the number of tumors in mice with lung cancer. The study also found that radiation treatments did not significantly impair the immune response. The paper was published on March 10 in the journal Cancer Immunology Research, an American Association for Cancer Research (AACR) publication.


"Though tecemotide, also known as Stimuvax, has shown great potential at times, the recent Phase III trial found no overall survival benefit for patients with non-small cell lung cancer (NSCLC). However, further analysis showed one group of patients, who received concurrent chemotherapy and radiation followed by tecemotide, did benefit from the vaccine. As a result, tecemotide's manufacturer, Merck KGaA, is sponsoring additional post-clinical animal and human studies, so far with good results."


Editor's note: Cancer vaccines are meant to stimulate the immune system to fight cancer. Stimuvax is a cancer vaccine that was found to have no overall survival benefit for patients in a recent clinical trial. But closer analysis of the trial data and the mouse study mentioned above have raised hopes that the vaccine might work with some combination of chemo and radiation treatment.

Cancer Commons's insight:

Medical Xpress  |  Mar 20, 2014

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

Novel Cancer Vaccine Fails to Improve Overall Survival in Lung Cancer Clinical Trial

Novel Cancer Vaccine Fails to Improve Overall Survival in Lung Cancer Clinical Trial | Lung Cancer Dispatch | Scoop.it

A phase III clinical trial investigating the novel cancer vaccine L-BLP25 (Stimuvax) found that it produced no significant improvement in overall patient survival. However, the drug did show promising results in certain subgroups of patients. The trial investigators therefore plan to conduct more detailed analyses of the trial data and will also move ahead with another phase III clinical trial testing the drug in a different patient population.


Primary source: http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=727708

Cancer Commons's insight:

OncLive | Dec 21, 2012

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Lung Cancer Vaccine Brought Back for New Clinical Trial

A new clinical trial will reexamine the lung cancer vaccine tecemotide, formerly known as Stimuvax. Tecemotide stimulates the patient's immune system to attack tumor cells. Although the drug previously failed in the START clinical trial, drugmakers reported that later analyses showed that tecemotide increased survival in the subset of patients who had been treated with chemoradiotherapy (simultaneous chemotherapy and radiation therapy, or CRT) before tecemotide. Like START, the new trial, START2, will enroll patients with locally advanced, stage III non-small cell lung cancer (NSCLC) that cannot be removed with surgery. However, START2 will exclusively focus on patients who have previously received CRT.

Cancer Commons's insight:

Reuters | Sep 25, 2013

more...
No comment yet.